Market Research Future (MRFR) asserts that the global lupus market is likely to garner a CAGR of 11.2% during the forecast period (2018-2023). Medical advancements in treating systemic lupus erythematosus is expected to push the market growth across the globe. Lupus can be referred to as a systemic autoimmune disease which causes inflammation, swelling, and pain, thereby causing damage throughout the body. The immune system attacks the healthy tissues and cells of the body in patients suffering from lupus. This further results in the damage to the joints, skin, heart, kidney, brain, lungs, and blood vessels. Several people tend to inherit lupus which is triggered due to infections of certain drugs, and even sunlight. It is characterized by the excessive production of antibodies which attack the body’s healthy cells and organs.
The Lupus market is expanding at breakneck speed across the globe due to the surging prevalence of lupus and the ongoing medical advancements in treating systemic lupus erythematosus. The increased research and development activities for lupus can be considered a propelling factor. As per the Lupus Foundation of America, approximately 1.5 million Americans are estimated to have a form of lupus and over 16,000 new cases are reported every year. With prominent market giants involving in new product launches and the development of new products, the market is predicted to evolve during the appraisal period. For instance, GlaxoSmithKline received approval from the FDA in July 2017 for developing a new self-injectable formulation of Benlysta which can treat systemic lupus erythematosus in adults.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6636
The prominent players operating in the lupus market comprises
- Bristol-Myers Squibb Company,
- Aurinia Pharmaceuticals Inc
- GlaxoSmithKline plc
- Cadila Healthcare
- F. Hoffmann-La Roche AG
- Mylan N.V.
- Pfizer Inc
- Merck KGaA
- Lycera Corporation
- Eli Lily and Company
- The global lupus market has been segmented on the basis of treatment, type, and end-user.
- By mode of type, the global lupus market has been segmented into cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus.
- By mode of treatment, the global lupus market has been segmented into antimalarial drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, corticosteroids, biologics, and other.
- By mode of end-users, the global lupus market has been segmented into diagnostic laboratories, hospital & clinics, and others. Among these, hospitals are estimated to occupy the major share as the treatment for lupus is highly preferred in the hospitals.
Get an Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/6636
Geographically, the lupus market spans across regions namely, Europe, America, Asia-Pacific, and the Middle East & Africa.
Considering the global scenario, the lupus market is dominated by the American region. The region is likely to retain its pole position owing to the surging demand for better treatment options, several government initiatives for lupus, increased incidences of lupus, and favorable reimbursement policies. Moreover, the accessibility to biologics and the well-developed healthcare infrastructure are contributing towards the growth.
The European region is predicted to acquire the second spot in the global market. The growth can be ascribed to the increased number of research and development activities coupled with the surging prevalence for lupus in this region. The five major countries of Europe like Germany, U.K., Italy, Spain, and France were the first to approve Benlysta for the treatment of Benlysta, which propels the market growth in this region. Moreover, the better coverage policies have resulted in higher adoption of belimumab, further stimulating the market growth.
The Asia Pacific region is estimated to expand at the fastest rate owing to the constantly evolving healthcare sector, surging prevalence of lupus, and regional expansion by the major market giants. As per the Australian Society of Clinical Immunology and Allergy, it was predicted that lupus affected more than 20,000 people in New Zealand and Australia in 2016.
April 29, 2019: The FDA has recently approved Benlysta for treating children from 5 years of age suffering from systemic lupus erythematosus. The approval allows the drug to be administered to patients of 5 years of age and older with active, autoantibody-positive SLE receiving standard therapy.
Acccess Full Report Details and Full TOC Exclusively @ https://www.marketresearchfuture.com/reports/lupus-market-6636
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar